Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFM 11

Next Previous
X
Search
Drug Profile

AFM 11

Alternative Names: AFM11

Latest Information Update: 30 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affimed Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen modulators; CD3 antigen modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 19 Jun 2019 Affimed terminates a phase I trial in Precursor B-cell lymphoblastic leukaemia-lymphoma in Austria, Czech republic, Israel, Poland and Russia due to its strategic decision to terminate the AFM 11 development(NCT02848911)
  • 27 May 2019 Discontinued - Phase-I for Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in Czech Republic, Israel, Poland, Russia, Austria (IV)
  • 16 May 2019 Affimed terminates a phase I dose-escalation trial in Non-Hodgkin lymphoma in USA, Czech Republic, Germany and Poland due to non-favorable risk/benefit profile with studied dosing regimen (NCT02106091)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top